



**HAL**  
open science

## Extracellular vesicles produced by the probiotic *Propionibacterium freudenreichii* CIRM-BIA 129 mitigate inflammation by modulating the NF- $\kappa$ B pathway

Vinicius de Rezende Rodovalho, Brenda Silva Rosa da Luz, Houem Rabah, Fillipe Luiz Rosa Do Carmo, Edson L Folador, Aurélie Nicolas, Julien Jardin, Valérie Briard-Bion, Herve Blottiere, Nicolas Lapaque, et al.

### ► To cite this version:

Vinicius de Rezende Rodovalho, Brenda Silva Rosa da Luz, Houem Rabah, Fillipe Luiz Rosa Do Carmo, Edson L Folador, et al.. Extracellular vesicles produced by the probiotic *Propionibacterium freudenreichii* CIRM-BIA 129 mitigate inflammation by modulating the NF- $\kappa$ B pathway. *Frontiers in Microbiology*, 2020, 11, 10.3389/fmicb.2020.01544 . hal-02885846

**HAL Id: hal-02885846**

**<https://hal.inrae.fr/hal-02885846>**

Submitted on 1 Jul 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

## Author's Proof

Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools ([Adobe Help](#)). We do not accept corrections in the form of edited manuscripts.

In order to ensure the timely publication of your article, please submit the corrections within 48 hours. If you have any questions, contact [microbiology.production.office@frontiersin.org](mailto:microbiology.production.office@frontiersin.org).

### Quick Check-List

- **Author names** - Complete, accurate and consistent with your previous publications.
- **Affiliations** - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country.
- **Tables** - Make sure our formatting style did not change the meaning/alignment of your Tables.
- **Figures** - Make sure we are using the latest versions.
- **Funding and Acknowledgments** - List all relevant funders and acknowledgments.
- **Conflict of Interest** - Ensure any relevant conflicts are declared.
- **Supplementary files** - Ensure the latest files are published and that no line numbers and tracked changes are visible.  
Also, the supplementary files should be cited in the article body text.
- **Queries** - Reply to all typesetters queries below.
- **Content** - Read all content carefully and ensure any necessary corrections are made.

## Author Queries Form

Query No.	Details required	Author's Response
<b>Q1</b>	The citation and surnames of all of the authors have been highlighted. Check that they are correct and consistent with the authors' previous publications, and correct if need be. Please note that this may affect the indexing of your article in repositories such as PubMed.	Please modify the first and second author citation name as specified next to them. Note that the family name of the first and second authors is Rodovalho and Luz, respectively.
<b>Q2</b>	Please ask the following authors to <a href="https://www.frontiersin.org/Registration/Register.aspx">register</a> with Frontiers (at <a href="https://www.frontiersin.org/Registration/Register.aspx">https://www.frontiersin.org/Registration/Register.aspx</a> ) if they would like their names on the article abstract page and PDF to be linked to a Frontiers profile. Please ensure to provide us with the profile link(s) when submitting the proof corrections. Non-registered authors will have the default profile image displayed. Brenda Silva Rosa da Luz Aur�lie Nicolas Julien Jardin Val�rie Briard-Bion Gwena�l Jan Yves Le Loir	OK
<b>Q3</b>	Confirm that the email address in your correspondence section is accurate.	OK
<b>Q4</b>	If you decide to use previously published, <a href="#">copyrighted</a> figures in your article, please keep in mind that it is your responsibility, as the author, to obtain the appropriate permissions and licenses and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors.	OK, There are no previously published figures in this article

<b>Query No.</b>	<b>Details required</b>	<b>Author's Response</b>
<b>Q5</b>	Ensure that all the figures, tables and captions are correct, and that all figures are of the highest quality/resolution.	Please, modify some of the captions as specified nexto to them.
<b>Q6</b>	Verify that all the equations and special characters are displayed correctly.	OK
<b>Q7</b>	Please confirm that the Data Availability statement is accurate. Note that we have used the statement provided at Submission. If this is not the latest version, please let us know.	Ok, we changed with the public link version (with a DOI)
<b>Q8</b>	Confirm that the details in the "Author Contributions" section are correct and note that we have added the sentence "All authors contributed to the article and approved the submitted version."	OK
<b>Q9</b>	Ensure to add all grant numbers and funding information, as after publication this will no longer be possible.	OK
<b>Q10</b>	Ensure that any supplementary material is correctly published at this link: <a href="https://www.frontiersin.org/articles/10.3389/fmicb.2020.01544/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fmicb.2020.01544/full#supplementary-material</a> Provide new files if you have any corrections and make sure all Supplementary files are cited. Please also provide captions for these files, if relevant. Note that ALL supplementary files will be deposited to FigShare and receive a DOI. Notify us of any previously deposited material.	OK
<b>Q11</b>	Kindly confirm whether the Affiliations are correct.	OK
<b>Q12</b>	Please provide expansion for "ELISA."	OK
<b>Q13</b>	Please include the symbol "*", "**", "***" and "****" within the artwork as specified in the Figure 6 caption.	OK
<b>Q14</b>	Please include the symbol "*" and "***" within the artwork as specified in the Figure 7 caption.	OK
<b>Q15</b>	Kindly confirm if the edit made in Acknowledgments section is fine.	OK



# Extracellular Vesicles Produced by the Probiotic *Propionibacterium freudenreichii* CIRM-BIA 129 Mitigate Inflammation by Modulating the NF- $\kappa$ B Pathway

Vinícius de Rezende R. **Rodvalho**<sup>1,2</sup>, Brenda Silva Rosa **da Luz**<sup>1,2</sup>, Houem **Rabah**<sup>1</sup>, Fillipe Luiz Rosa **do Carmo**<sup>2</sup>, Edson Luiz **Folador**<sup>3</sup>, Aurélie **Nicolas**<sup>1</sup>, Julien **Jardin**<sup>1</sup>, Valérie **Briard-Bion**<sup>1</sup>, Hervé **Blottière**<sup>4</sup>, Nicolas **Lapaque**<sup>4</sup>, Gwenaél **Jan**<sup>1</sup>, Yves **Le Loir**<sup>1</sup>, Vasco Ariston **de Carvalho Azevedo**<sup>2</sup> and Eric **Guédon**<sup>1\*</sup>

## OPEN ACCESS

### Edited by:

Jasna Novak (maiden Beganovic),  
University of Zagreb, Croatia

### Reviewed by:

Haruki Kitazawa,  
Tohoku University, Japan  
Julio Villena,  
CONICET Centro de Referencia para  
Lactobacilos (CERELA), Argentina  
Veera Kainulainen,  
University of Helsinki, Finland

### \*Correspondence:

Eric Guédon  
eric.guedon@inrae.fr

### Specialty section:

This article was submitted to  
Food Microbiology,  
a section of the journal  
Frontiers in Microbiology

**Received:** 09 March 2020

**Accepted:** 15 June 2020

**Published:** xx June 2020

### Citation:

de Rezende Rodvalho V, da Luz BSR, Rabah H, do Carmo FLR, Folador EL, Nicolas A, Jardin J, Briard-Bion V, Blottière H, Lapaque N, Jan G, Le Loir Y, de Carvalho Azevedo VA and Guédon E (2020) Extracellular Vesicles Produced by the Probiotic *Propionibacterium freudenreichii* CIRM-BIA 129 Mitigate Inflammation by Modulating the NF- $\kappa$ B Pathway. *Front. Microbiol.* 11:1544. doi: 10.3389/fmicb.2020.01544

<sup>1</sup> INRAE, Institut Agro, STLO, Rennes, France, <sup>2</sup> Laboratory of Cellular and Molecular Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil, <sup>3</sup> Biotechnology Center, Federal University of Paraíba, João Pessoa, Brazil, <sup>4</sup> INRAE, AgroParisTech, Paris-Saclay University, Micalis Institute, Jouy-en-Josas, France

Extracellular vesicles (EVs) are nanometric spherical structures involved in intercellular communication, whose production is considered to be a widespread phenomenon in living organisms. Bacterial EVs are associated with several processes that include survival, competition, pathogenesis, and immunomodulation. Among probiotic Gram-positive bacteria, some *Propionibacterium freudenreichii* strains exhibit anti-inflammatory activity, notably via surface proteins such as the surface-layer protein B (SlpB). We have hypothesized that, in addition to surface exposure and secretion of proteins, *P. freudenreichii* may produce EVs and thus export immunomodulatory proteins to interact with the host. In order to demonstrate their production in this species, EVs were purified from cell-free culture supernatants of the probiotic strain *P. freudenreichii* CIRM-BIA 129, and their physicochemical characterization, using transmission electron microscopy and nanoparticle tracking analysis (NTA), revealed shapes and sizes typical of EVs. Proteomic characterization showed that EVs contain a broad range of proteins, including immunomodulatory proteins such as SlpB. *In silico* protein-protein interaction predictions indicated that EV proteins could interact with host proteins, including the immunomodulatory transcription factor NF- $\kappa$ B. This potential interaction has a functional significance because EVs modulate inflammatory responses, as shown by IL-8 release and NF- $\kappa$ B activity, in HT-29 human intestinal epithelial cells. Indeed, EVs displayed an anti-inflammatory effect by modulating the NF- $\kappa$ B pathway; this was dependent on their concentration and on the proinflammatory inducer (LPS-specific). Moreover, while this anti-inflammatory effect partly depended on SlpB, it was not abolished by EV surface proteolysis, suggesting possible intracellular sites of action for EVs. This is the first report on identification of *P. freudenreichii*-derived

EVs, alongside their physicochemical, biochemical and functional characterization. This study has enhanced our understanding of the mechanisms associated with the probiotic activity of *P. freudenreichii* and identified opportunities to employ bacterial-derived EVs for the development of bioactive products with therapeutic effects.

**Keywords:** extracellular vesicles, membrane vesicles, probiotic, propionibacteria, immunomodulation, anti-inflammatory, IL-8, NF- $\kappa$ B

## INTRODUCTION

Intercellular communication is an essential biological process that involves several soluble biomolecules that may be secreted, surface-exposed or packed inside extracellular vesicles (EVs) (Gho and Lee, 2017; Toyofuku, 2019). EVs are lipid bilayer nanoparticles which range in size from 20 to 300 nm and are released by cells from all living kingdoms (Brown et al., 2015; Kim et al., 2015a; Liu et al., 2018a). They play a pivotal role in cell-to-cell communication through their ability to transport bioactive molecules (proteins, nucleic acids, lipids, metabolites) from donor to recipient cells. Bacterial EVs are implicated in virulence factor delivery, antibiotic resistance, competition, survival, and host cell modulation (Kim et al., 2015b; Toyofuku et al., 2019).

The participation of EVs in the beneficial roles of probiotic bacteria has been increasingly reported (Molina-Tijeras et al., 2019). The release of EVs by *Lactobacillus* species is well documented; *Lactobacillus reuteri* DSM 17938-derived EVs are associated with extracellular DNA-dependent biofilm formation (Grande et al., 2017) and EVs secreted by *Lactobacillus casei* BL23 have also been reported and shown to contain diverse biomolecules which include nucleic acids and proteins previously associated with its probiotic effects, such as p40 and p75 (Rubio et al., 2017). *Lactobacillus rhamnosus* GG-derived EVs have been associated with the apoptosis of hepG2 cancer cells (Behzadi et al., 2017), and *Lactobacillus plantarum* WCFS1-derived EVs modulated the response of human cells to vancomycin-resistant enterococci (Li et al., 2017). Moreover, EVs derived from other probiotic species, such as *Bifidobacterium longum* KACC 91563, impact host cell responses by inducing mast cell apoptosis, which has implications for the treatment of food allergies (Kim et al., 2016). Furthermore, probiotic strains of *Escherichia coli* release outer membrane vesicles (OMVs) that are involved in reinforcement of the gastrointestinal epithelial barrier (Alvarez et al., 2016), the regulation of inflammatory responses and intestinal homeostasis, via the NOD1-signaling pathway (Cañas et al., 2018).

*Propionibacterium freudenreichii* has also been regarded consistently as a probiotic species, mainly because of its immunomodulatory properties and protective effects against experimentally induced inflammation *in vivo* (Lan et al., 2007a, 2008; Foligne et al., 2010; Cousin et al., 2012; Rabah et al., 2018a; Do Carmo et al., 2019). *P. freudenreichii* is a Gram-positive, pleiomorphic, microaerophilic dairy bacterium that is generally recognized as safe (GRAS) and has a qualified presumption of safety (QPS) status (Loux et al., 2015; Deutsch et al., 2017; Rabah et al., 2017). This species is also known for its involvement in the

ripening, texture, and flavor of cheese (Ojala et al., 2017) and in vitamin B12 synthesis (Deptula et al., 2017). A *P. freudenreichii* strain was recently isolated from the gut microbiota of a human breast milk-fed preterm infant, suggesting that this species could also be considered as a commensal inhabitant of the human digestive tract (Colliou et al., 2017).

As for the molecular mechanisms underlying its probiotic effects, some studies have focused on identifying the surface proteins of *P. freudenreichii* and their role in cytokine induction (Le Maréchal et al., 2015; Deutsch et al., 2017; Do Carmo et al., 2019). Notably, cell wall-related proteins, S-layer type proteins, moonlighting proteins and proteins related to interactions with the host have been identified as important actors in immunomodulation of *P. freudenreichii* strain CIRM-BIA 129 (Le Maréchal et al., 2015). Specifically, recent studies reported the role of surface-layer protein B (SlpB) from this strain in bacterial adhesion to intestinal HT-29 cells and immunomodulation (Do Carmo et al., 2017, 2019; Rabah et al., 2018b), as well as that of large surface layer protein A (LspA) from strain P. UF1 in the regulation of colonic dendritic cells during inflammation via SIGNR1 binding (Ge et al., 2020). As well as surface proteins, additional metabolites may contribute to the probiotic effect, such as 1,4-Dihydroxy-2-naphthoic acid (DHNA) from *P. freudenreichii* ET3, which is linked to AhR pathway activation (Fukumoto et al., 2014). DHNA has also been implicated in colitis regression (Okada et al., 2013). Moreover, short-chain fatty acids (SCFAs) from strains TL133 and TL142 have been demonstrated to play a role in inducing apoptosis of tumor cell lines (Lan et al., 2007b, 2008; Cousin et al., 2016).

In view of the fact that EVs are emerging as important carriers of biologically active cargos and that vesiculogenesis is a generally occurring phenomenon, we hypothesized that they might explain some of the probiotic properties of *P. freudenreichii*. For the first time, our findings have shown that this species produces EVs, and we have characterized their physicochemical, biochemical and functional features. We report that *P. freudenreichii* CIRM-BIA 129-derived EVs are implicated in its anti-inflammatory properties, via modulation of the NF- $\kappa$ B pathway, thus building on knowledge regarding this important probiotic bacterium.

## MATERIALS AND METHODS

### Bacterial Strain and Growth Conditions

*Propionibacterium freudenreichii* CIRM-BIA 129 (equivalent to the ITG P20 strain) was supplied, stored and maintained by the CIRM-BIA Biological Resource Center (Centre International de Ressources Microbiennes-Bactéries d'Intérêt Alimentaire, INRA,

229 Rennes, France). *P. freudenreichii* CIRM-BIA 129 and its isogenic  
230 *P. freudenreichii* CIRM-BIA 129  $\Delta$ *slpB* mutant strain (Do  
231 Carmo et al., 2017) were cultured in cow milk ultrafiltrate (UF)  
232 supplemented with 100 mM sodium lactate and 5 g L<sup>-1</sup> casein  
233 hydrolysate at 30°C and without agitation, until stationary phase  
234 (72 h of incubation, 2 × 10<sup>9</sup> CFU mL<sup>-1</sup>), as reported previously  
235 (Cousin et al., 2012).

## 236 Purification of EVs

237 Cells were pelleted by the centrifugation (6000 g, 15 min,  
238 room temperature) of cultures in UF (500 mL) and the  
239 supernatant fraction was filtered using 0.22 μm Nalgene top  
240 filters (Thermo Scientific) to remove any remaining bacterial  
241 cells. The supernatant was then concentrated 1000 times using  
242 Amicon ultrafiltration units with a 100 kDa cut-off point  
243 in successive centrifugations at 2500 g. The concentrated  
244 suspension of EVs was recovered in TBS buffer (Tris-Buffered  
245 Saline, 150 mM NaCl; 50 mM Tris-HCl, pH 7.5) and further  
246 purified by size exclusion chromatography (qEV original 70 nm;  
247 iZON), as recommended by the manufacturer (Böing et al.,  
248 2014). Briefly, 0.5 mL of EV samples was applied to the  
249 top of the chromatographic column, followed by TBS buffer  
250 for elution. Then, fractions of 0.5 mL were recovered in  
251 separate tubes. Fractions 1–6 were discarded as void, EVs-  
252 containing fractions (fractions 7–9) were pooled together and the  
253 remaining fractions were discarded due to protein contamination  
254 or low EV content.

## 255 Negative Staining for Transmission 256 Electron Microscopy

257 To characterize the shape of purified EVs, negative staining  
258 electron microscopy was conducted as previously described  
259 (Tartaglia et al., 2018). Briefly, a drop of EV solution was applied  
260 on a glow-discharged formvar-coated copper EM grid and blotted  
261 with a filter paper to remove excess solution. A drop of 2% uranyl  
262 acetate was applied to the EM grid, blotted again and finally  
263 dried before imaging under a Jeol 1400 transmission electron  
264 microscope (JEOL Ltd.) operating at 120 Kv.

## 265 Nanoparticle Tracking Analysis for EV 266 Size and Concentration Assessment

267 To measure the size and concentration of EVs, nanoparticle  
268 tracking analysis (NTA) was performed at 25.0°C using a  
269 NanoSight NS300 instrument (Malvern Panalytical) with a  
270 sCMOS camera and a Blue488 laser (Mehdiani et al., 2015).  
271 Samples were applied in constant flux with a syringe pump speed  
272 of 50. For each measurement, 560-s videos were recorded with  
273 camera level 15. Other parameters were adjusted accordingly to  
274 achieve image optimization.

## 275 Proteomic Analysis

276 Three independent biological replicates of purified EVs from  
277 *P. freudenreichii* CIRM-BIA 129 (approximately 1 μg per sample)  
278 and the whole cell proteome were separated and visualized using  
279 12% SDS-PAGE (Laemmli, 1970) and silver staining (Switzer  
280 et al., 1979). Next, EV proteins were hydrolyzed with trypsin for

281 NanoLC-ESI-MS/MS analysis, as previously described (Gagnaire  
282 et al., 2015; Huang et al., 2016). Briefly, gel pieces were washed  
283 with acetonitrile and ammonium bicarbonate solution and dried  
284 under a vacuum. Next, in-gel trypsin digestion was performed  
285 overnight at 37°C and stopped with trifluoroacetic acid (Sigma-  
286 Aldrich). After digestion, the peptides were identified from  
287 the MS/MS spectra using X!TandemPipeline software (Langella  
288 et al., 2017) and searches were performed against the genome  
289 sequence of *P. freudenreichii* CIRM-BIA 129. The database  
290 search parameters were specified as follows: trypsin cleavage  
291 was used and the peptide mass tolerance was set at 10 ppm  
292 for MS and 0.05 Da for MS/MS. Methionine oxidation was  
293 selected as a variable modification. For each peptide identified,  
294 a minimum *e*-value of 0.05 was considered to be a prerequisite  
295 for validation. A minimum of two peptides per protein was  
296 imposed, resulting in a false discovery rate (FDR) of 0.15% for  
297 protein identification.

298 Proteomic data were further analyzed and visualized using  
299 Python libraries Pandas, NumPy, Matplotlib, and Seaborn.  
300 Functional annotations and Clusters of Orthologous Groups  
301 (COGs) were obtained using the eggNOG-mapper v2 web tool  
302 (Huerta-Cepas et al., 2017, 2019), while proteins and gene  
303 data were retrieved from NCBI and Uniprot (Bateman, 2019).  
304 Subcellular location prediction was performed with CELLO2GO  
305 (Yu et al., 2014) and the prediction of lipoproteins was conducted  
306 using PRED\_LIPO (Bagos et al., 2008).

## 307 Prediction of Protein-Protein Interactions

308 In order to screen for potential biological functions of EVs,  
309 the prediction of interactions between EV proteins and human  
310 proteins was carried out. The reference human proteome  
311 was retrieved from Uniprot (UP000005640) and contained  
312 74,788 protein sequences. For the first method of prediction,  
313 EVs and human proteins were submitted to the InterSPPI  
314 web server (Lian et al., 2019), a machine-learning-based  
315 predictor. For the second method of prediction, a interolog-  
316 based approach was used (Folador et al., 2014), establishing  
317 homology relationships with the interactions described in the  
318 String and Intact databases (Kerrien et al., 2012; Szklarczyk  
319 et al., 2017). The resulting interactions were filtered according  
320 to the prediction scores (intersppi: minimum score of 0.9765,  
321 for a specificity 0.99; interolog: minimum score of 500 out  
322 of 1000). Next, the dataset was reduced to a canonical  
323 representation, only retaining the human protein isoform  
324 appearing in highest-scoring interactions and removing non-  
325 reviewed human proteins. For the predicted interactions, the  
326 human counterpart was programmatically mapped to KEGG  
327 pathways in order to identify the associated functional modules.  
328 Data analysis and graphic representations were obtained using  
329 Python libraries Pandas, Seaborn, Matplotlib, Matplotlib\_venn,  
330 and Cytoscape software (Shannon, 2003).

## 331 Culture of Eukaryotic Cells

332 HT-29 human epithelial cells were used for immunomodulation  
333 assays; either the parental lineage (HT-29, colon  
334 adenocarcinoma; ATCC HTB-38) or a lineage transfected  
335 with the secreted alkaline phosphatase (SEAP) reporter  
336

343 gene for NF- $\kappa$ B activation monitoring (HT-29/kb-seap-25)  
 344 (Lakhdari et al., 2010). The reporter HT-29/kb-seap-25 cells  
 345 were cultured in RPMI-Glutamine medium (Sigma-Aldrich),  
 346 supplemented with 10% fetal bovine serum (Corning), 1%  
 347 non-essential amino acids, 1% sodium pyruvate, 1% HEPES  
 348 buffer (ThermoFisher Scientific), and 1% penicillin-streptomycin  
 349 (Lonza) according to Lakhdari et al. (2010). The parental  
 350 HT-29 cells were cultured in high-glucose DMEM medium  
 351 (Dominique Dutscher) supplemented with 10% fetal bovine  
 352 serum and 1% penicillin-streptomycin (Do Carmo et al., 2017).  
 353 For subcultures, cells were rinsed with DPBS (ThermoFisher  
 354 Scientific) and detached with a trypsin (0.05%) – EDTA (0.02%)  
 355 solution (Sigma). Periodically, 100  $\mu$ g/mL Zeocin (Invivogen)  
 356 was applied to the HT-29/kb-seap-25 cell culture in order  
 357 to maintain selective pressure on the cells containing the  
 358 transfected plasmid.

### 359 NF- $\kappa$ B Modulation Assays

361 HT-29/kb-seap-25 cells were seeded on 96-well plates at  $3 \times 10^4$   
 362 cells/well and incubated for 24 h at 37°C under 5% CO<sub>2</sub> prior  
 363 to stimulation (Lakhdari et al., 2010). Monolayer confluence  
 364 was checked under the microscope before and after every  
 365 stimulation. TNF $\alpha$  (1  $\mu$ g mL<sup>-1</sup>; PeproTech), IL-1 $\beta$  (1  $\mu$ g  
 366 mL<sup>-1</sup>; Invivogen), and LPS from *E. coli* O111:B4 (1  $\mu$ g mL<sup>-1</sup>;  
 367 L3024-5MG, Sigma-Aldrich) were used to induce inflammation.  
 368 The cells were stimulated with the samples (controls and  
 369 EV preparations) and inflammation inducers for 24 h. The  
 370 supernatants from all the wells were then revealed with  
 371 Quanti-Blue™ reagent (Invivogen) to assess SEAP activity.  
 372 Cell proliferation was evaluated under all conditions using the  
 373 CellTiter 96® Aqueous One Solution Cell Proliferation Assay  
 374 (MTS, Promega), according to the manufacturer's instructions.  
 375 Absorbance was read at 655 nm for the SEAP activity assay and  
 376 at 490 nm for the MTS assay using a Xenius (SAFAS Monaco)  
 377 microplate reader. For surface protein assays, 10<sup>9</sup> EV ml<sup>-1</sup>  
 378 were applied directly or after incubation at 37°C for 1 h in the  
 379 presence or absence of proteinase K (20  $\mu$ g mL<sup>-1</sup>; Qiagen),  
 380 in order to evaluate a possible role for EV surface proteins in  
 381 immunomodulation.

### 382 ELISA Cytokine Assay

384 **Q12** ELISA tests were performed under the same conditions as the  
 385 NF- $\kappa$ B modulation assays using HT-29 parental cells. The human  
 386 IL-8/CXCL8 DuoSet (R&D Systems) kit was used to evaluate  
 387 cell culture supernatants after stimulation, according to the  
 388 manufacturer's instructions. Absorbance was read at 450 nm  
 389 using a Xenius (SAFAS Monaco) microplate reader.

### 392 Statistical Analysis

393 All experiments were conducted independently and in triplicate  
 394 at least, and the results are expressed as means  $\pm$  standard  
 395 deviations of biological replicates. For absorbance measurements,  
 396 the values were normalized by the control condition. The  
 397 differences between groups were verified using one-way ANOVA  
 398 followed by Tukey's multiple comparisons test with GraphPad  
 399 Prism (GraphPad Software, San Diego, CA, United States).

## RESULTS

### 400 *Propionibacterium freudenreichii* 401 Produces Extracellular Vesicles


402 In order to determine whether *P. freudenreichii* produced  
 403 EVs, strain CIRM-BIA 129 was cultured in cow milk UF  
 404 medium and EVs were purified from the cell-free supernatants  
 405 of stationary phase cultures. As a control, we checked that  
 406 EVs were absent from the UF medium before being used  
 407 for bacterial culture. Visualization by electron microscopy  
 408 revealed that *P. freudenreichii* strain CIRM-BIA 129 produced  
 409 EVs of a typical shape, i.e., spherical cup-shaped structures  
 410 (Figure 1A). Size characterization by NTA showed that the  
 411 EVs presented a monodisperse profile with modal diameter of  
 412 84.80  $\pm$  2.34 nm (Figure 1B).  
 413  
 414  
 415

### 416 *P. freudenreichii*-Secreted EVs Contain a 417 Functionally Diverse Set of Proteins, 418 Including Immunomodulatory Proteins

419 Cargo proteins associated with *P. freudenreichii*-secreted EVs  
 420 were determined by Nano LC-ESI-MS/MS analysis from three  
 421 biological replicates of EVs. A total of 319 proteins was  
 422 identified consistently in EVs derived from UF medium cultures  
 423 (Supplementary Table S1), which corresponds to 11% of the  
 424 whole theoretical proteome of *P. freudenreichii* CIRM-BIA 129.  
 425 Figure 2A confirmed a much more complex proteome in the  
 426 whole cell *P. freudenreichii* extract than in the EV extract.  
 427

428 The proteins associated with these EVs were distributed  
 429 between most of the COG categories (Figure 2B). The majority  
 430 of proteins could be assigned to COGs related to the general  
 431 category of "metabolism," e.g., energy production and conversion  
 432 (C, 14.8%), amino acid transport and metabolism (E, 10.4%),  
 433 and carbohydrate transport and metabolism (G, 8%). The  
 434 most common COGs in the general category of "information,  
 435 storage and processing" were translation, ribosomal structure  
 436 and biogenesis (J, 7.1%) and transcription (K, 4.2%). Finally,  
 437 cell wall/membrane/envelope biogenesis (M, 5.3%) and post-  
 438 translational modifications, protein turnover and chaperones  
 439 (O, 5%), were the most frequently counted COGs in the general  
 440 category of "cellular processes and signaling." Interestingly,  
 441 several proteins previously identified as important actors in  
 442 immunomodulation were packed within EVs: enolase (Eno1,  
 443 PFCIRM129\_06070), aconitase (Acn, PFCIRM129\_04640),  
 444 glutamine synthetase (GlnA1, PFCIRM129\_11730), glucose-6-  
 445 phosphate isomerase (Gpi, PFCIRM129\_10645), triosephosphate  
 446 isomerase (Tpi1, PFCIRM129\_11290), the surface-layer proteins  
 447 SlpB (PFCIRM129\_00700) and SlpE (PFCIRM129\_05460),  
 448 the BopA solute binding protein (PFCIRM129\_08120),  
 449 internaline A (InlA, PFCIRM129\_12235), the hypothetical  
 450 protein PFCIRM129\_10785 and the GroL2 chaperonin  
 451 (PFCIRM129\_10100) (Le Maréchal et al., 2015; Deutsch  
 452 et al., 2017; Do Carmo et al., 2017).

453 Regarding predictions of the subcellular localization of  
 454 the proteins, they were mainly predicted to be cytoplasmic  
 455 ( $n = 239$ ), but some membrane ( $n = 51$ ), and extracellular  
 456 ( $n = 29$ ) proteins were also identified (Figure 2C). Lipoprotein



**FIGURE 1** | *P. freudenreichii* CIRM-BIA 129 secretes extracellular vesicles. **(A)** Transmission electron microscopy images after the negative staining of *P. freudenreichii*-secreted EVs purified from UF culture supernatants. **(B)** Size distribution (diameter) of purified EVs as measured by nanoparticle tracking analysis (NTA). Concentration data are expressed as mean  $\pm$  standard deviation from three independent biological replicates.

signal peptides were also predicted in a small fraction of the proteins ( $n = 22$ ). Other proteins were predicted to contain a secretory signal peptide I ( $n = 22$ ) and transmembrane motifs ( $n = 34$ ) (Figure 2D). Regarding the protein abundance index (Ishihama et al., 2005), it displayed a non-normal distribution with a tail of highly expressed proteins, including immunomodulatory SlpB, 60 kDa chaperonin 2 (GroL2) and enolase 1 (Eno1), as well as cold shock-like protein CspA, iron/manganese superoxide dismutase (SodA), cysteine synthase 2 (Cys2), alkyl hydroperoxide reductase subunit C (AhpC), and malate dehydrogenase (Mdh) (Figure 2E).

### The Proteins From *P. freudenreichii*-Secreted EVs Potentially Interact With Human Immunomodulatory Proteins


The proteins found in *P. freudenreichii*-derived EVs were tested against the human proteome *in silico* in order to predict their interactions. Machine learning-based (intersppi) and homology-based (interolog) methods were employed for this task. There was a considerable difference regarding the number of predicted interactions which depended on the method used. Intersppi predicted 117,513 interactions, while the interolog method predicted 2,890 interactions; there were 143 common interactions between the two methods (Figure 3A and Supplementary Tables S2–S4). Regarding interacting bacterial proteins, 115 proteins appeared exclusively in intersppi interactions, 51

proteins appeared exclusively in interolog interactions and 90 proteins appeared in interactions predicted by both methods (Figure 3B and Supplementary Table S5). As for interacting human proteins, the majority was predicted by the intersppi method only (6,883 proteins), whereas 747 proteins appeared exclusively in interolog interactions and 611 proteins appeared in interactions shared by both methods of prediction (Figure 3C and Supplementary Table S6).

The predicted interactions mapped to diverse KEGG terms, including metabolism, signal transduction, infectious diseases and the immune system (Supplementary Figure S1). Interestingly, the nuclear factor NF- $\kappa$ B p105 subunit (NFKB1, P19838) was the most frequent interacting human protein considering common and intersppi-exclusive interactions. The subnetwork of interactions mapping to the KEGG NF- $\kappa$ B signaling pathway (Figure 3D) included both interactions with adapter molecules (e.g., TICAM1, TICAM2, TRAF6) and Toll-like receptors (e.g., TLR1, TLR4, TLR5, TL6), as well as NFKB1 itself (Supplementary Figures S2, S3). These results therefore indicated some interesting potential roles for EV proteins in immunomodulation that need to be verified experimentally.

### *P. freudenreichii*-Secreted EVs Modulate the NF- $\kappa$ B Pathway in a Dose and Inducer-Dependent Manner

In view of the finding that *in silico* predictions showed interactions between EV proteins and human




immunomodulatory proteins (and particularly NFKB1), together with previous evidence of immunomodulatory roles for *P. freudenreichii*, we investigated this potential *in vitro*. A cellular reporter system regarding modulation of the regulatory activity of the NF- $\kappa$ B transcription factor (HT-29/kb-seap-25) was therefore employed (Lakhdari et al., 2010). Cells were kept in contact with proinflammatory inducers (LPS, TNF- $\alpha$  or IL-1 $\beta$ ) and EV preparations, in order to test the ability of EVs to attenuate the induced inflammatory response.

Among cells that were not treated with proinflammatory inducers, their exposure to EVs did not affect the activity of the reporter, keeping a basal level of NF- $\kappa$ B activity (Figure 4A). When HT-29/kb-seap-25 cells were treated with LPS in the absence of EVs, NF- $\kappa$ B activation increased, thus showing LPS-dependent induction of the NF- $\kappa$ B pathway. With the addition of EVs at increasing concentrations, a dose-dependent reduction of NF- $\kappa$ B activation was observed. With

the highest EV concentration tested ( $1.0 \times 10^9$  EVs ml $^{-1}$ ), NF- $\kappa$ B activation was comparable to that of untreated control cells. Furthermore, when the EV concentration was kept at a constant level, NF- $\kappa$ B modulation was also dependent on the pathway inducer. In the presence of EVs, there was a significant reduction in NF- $\kappa$ B activation in LPS-treated cells, but not in cells treated with other inducers (TNF- $\alpha$  and IL-1 $\beta$ ) (Figure 4B).

### *P. freudenreichii*-Secreted EVs Also Modulate IL-8 Release in a Dose and Inducer-Dependent Manner

To further investigate the anti-inflammatory role suggested by the reduction in NF- $\kappa$ B activity, release of the proinflammatory chemokine IL-8 by HT-29 cells was determined in the presence of various EV concentrations and proinflammatory inducers.



742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786

In the absence of proinflammatory inducers, EVs had no effect on IL-8 release from HT-29 cells (**Figure 5A**). In the TBS buffer control group, LPS-treated HT-29 cells displayed an increase in IL-8 release when compared to untreated cells, reflecting the LPS-induced proinflammatory effect. In the presence of EVs, a significant and dose-dependent decrease of IL-8 release by LPS-stimulated cells was observed. At the highest concentration ( $1.0 \times 10^9$  EVs  $\text{ml}^{-1}$ ), IL-8 release was reduced down to a level comparable to that seen in untreated control cells.

739  
740  
741

Moreover, as in the case of NF- $\kappa$ B activity, the EV-mediated reduction in IL-8 release was specific to treatment with the LPS proinflammatory inducer (**Figure 5B**). When cells were treated


742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786

with TNF- $\alpha$  or IL-1 $\beta$ , no effect of EVs could be detected on IL-8 release by HT-29 cells. Taken together, these results showed that *P. freudenreichii*-derived EVs were endowed with anti-inflammatory properties that depended on the concentration and inflammatory stimulus.


### ***P. freudenreichii*-Secreted EVs Are Not Cytotoxic Against Intestinal Epithelial Cells**

793  
794  
795  
796  
797  
798  
799  
800

In order to ensure that reductions in NF- $\kappa$ B activation and IL-8 release were associated with regulatory




**FIGURE 4** | *P. freudenreichii*-secreted EVs specifically mitigate LPS-induced NF- $\kappa$ B activation in intestinal epithelial cells. **(A)** Measure of regulatory activity of the NF- $\kappa$ B transcription factor in HT-29 intestinal epithelial cells untreated or treated with LPS ( $1 \text{ ng } \mu\text{L}^{-1}$ ) in the presence of TBS buffer control or different concentrations of EVs purified from the supernatants of *P. freudenreichii* CIRM-BIA 129 culture in UF medium. EV concentrations: 0.01 =  $1.0 \times 10^7$  EVs  $\text{mL}^{-1}$ , 0.1 =  $1.0 \times 10^8$  EVs  $\text{mL}^{-1}$ , 0.25 =  $2.5 \times 10^8$  EVs  $\text{mL}^{-1}$ , 0.5 =  $5.0 \times 10^8$  EVs  $\text{mL}^{-1}$ , 1 =  $1.0 \times 10^9$  EVs  $\text{mL}^{-1}$ . **(B)** Percentage NF- $\kappa$ B activation in HT-29 intestinal epithelial cells after stimulation by LPS ( $1 \text{ ng } \mu\text{L}^{-1}$ ), TNF- $\alpha$  ( $1 \text{ ng } \mu\text{L}^{-1}$ ) or IL-1 $\beta$  ( $1 \text{ ng } \mu\text{L}^{-1}$ ) inducers, in the presence or absence of UF-derived EVs ( $1.0 \times 10^9$  EVs  $\text{mL}^{-1}$ ). The values are normalized by the control conditions (stimulation by the inducer in the absence of EVs). ANOVA with the Tukey's multiple comparison test: \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .



**FIGURE 5** | *P. freudenreichii*-secreted EVs mitigate the release of IL-8 induced by LPS. **(A)** Concentration of IL-8 ( $\text{pg mL}^{-1}$ ) released by HT-29 intestinal epithelial cells untreated or treated with LPS ( $1 \text{ ng } \mu\text{L}^{-1}$ ) in the presence of different concentrations of EVs purified from the supernatants of *P. freudenreichii* CIRM-BIA 129 culture in UF medium. EV concentrations: 0.01 =  $1.0 \times 10^7$  EVs  $\text{mL}^{-1}$ , 0.1 =  $1.0 \times 10^8$  EVs  $\text{mL}^{-1}$ , 0.5 =  $5.0 \times 10^8$  EVs  $\text{mL}^{-1}$ , 1 =  $1.0 \times 10^9$  EVs  $\text{mL}^{-1}$ . **(B)** Percentage of IL-8 released by HT-29 intestinal epithelial cells after stimulation by LPS ( $1 \text{ ng } \mu\text{L}^{-1}$ ), TNF- $\alpha$  ( $1 \text{ ng } \mu\text{L}^{-1}$ ) or IL-1 $\beta$  ( $1 \text{ ng } \mu\text{L}^{-1}$ ) inducers, in the presence or absence of UF-derived EVs ( $1.0 \times 10^9$  EVs  $\text{mL}^{-1}$ ). The values are normalized by the control conditions (stimulation by inducer in the absence of EVs). One-way ANOVA followed by Tukey's (left panel) or Dunnett's (right panel) multiple comparisons test: \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

activity and not simply with cell death, an MTS cell proliferation assay was also performed (Figure 6). This assay showed that there was no significant difference

in cell viability between the control and test groups in terms of both parental HT-29 and HT-29/kb-seap-25 reporter cells.



## Influence of Surface Proteins on NF- $\kappa$ B Modulation

Further tests were performed to determine whether the modulation of NF- $\kappa$ B by *P. freudenreichii* EVs was influenced by a surface-layer protein (SlpB), recognized as being immunomodulatory in the studied strain (Deutsch et al., 2017; Do Carmo et al., 2017; Figure 7). EVs derived from an isogenic mutant *P. freudenreichii* CIRM-BIA 129  $\Delta$ slpB and proven not to produce this specific protein, displayed a partial reduction of NF- $\kappa$ B activation, when compared to wild-type-derived EVs. This suggested that SlpB plays a fundamental role in EV modulation of the NF- $\kappa$ B pathway, but it is likely that other important effectors also need to be considered.


Furthermore, in order to determine whether NF- $\kappa$ B pathway modulation by EVs is dependent on proteins that might be exposed on the EV surface, they were treated with proteinase K prior to the cellular assays (Figure 7). The incubation of EVs at 37°C for 1 h, in the presence or absence of proteinase K, did not result in significant differences in NF- $\kappa$ B activation, when compared to the wild-type untreated control. This suggested that these immunomodulatory effectors may be inside EVs and not at their surface.

## DISCUSSION

Although research on bacterial EVs focused initially on Gram-negative and pathogenic bacteria, a major increase in the number of studies involving Gram-positive and probiotic bacteria has been seen during the past decade (Liu et al., 2018b; Molina-Tijeras et al., 2019). That is in line with the growing recognition of the widespread occurrence and diverse functions of EVs (Brown et al., 2015; Liu et al., 2018a,b). In the case of *P. freudenreichii*, a Gram-positive dairy probiotic bacterium,

a recent study indicated the presence of an extracellular structure resembling a potential EV, which bulged out from the membrane of *P. freudenreichii* strain JS22 (Frohnmeier et al., 2018), suggesting that this species might produce EVs. Nevertheless, ours is the first complete report to have identified the occurrence of EVs in *P. freudenreichii* strain CIRM-BIA 129, and included their physicochemical, biochemical and functional characterization. The EVs thus identified displayed the basic features of extracellular prokaryotic membrane vesicles, i.e., a nanometric size range, a cup-shaped morphology and a spherical structure (Raposo and Stoorvogel, 2013; Liu et al., 2018b; Tartaglia et al., 2018).

Extracellular vesicles carry a diverse set of proteins that represent a broad range of biological functions. More than half of these proteins are related to metabolism, so that, initially, they may not appear to exert specific functions outside bacterial cells. However, the transport of metabolism-related proteins by EVs may represent a mechanism of functional exchange and complementation in the context of bacterial communities. For example, members of the *Bacteroides* genus share enzymes with the microbiome through OMVs, so as to contribute to the degradation of complex polysaccharides (Elhenawy et al., 2014; Rakoff-Nahoum et al., 2014; Lynch and Alegado, 2017). On the other hand, some of these metabolism-related proteins, from either *P. freudenreichii* CIRM-BIA 129, or from other strains in the species, have been implicated in interactions with the host. This is the case of enolase (Eno1, PFCIRM129\_06070) and aconitase (Acn, PFCIRM129\_04640) (Deutsch et al., 2017). Others, such as glutamine synthetase (GlnA1, PFCIRM129\_11730), glucose-6-phosphate isomerase (Gpi, PFCIRM129\_10645) and triosephosphate isomerase (Tpi1, PFCIRM129\_11290), have also been described as moonlighting proteins, with adhesin functions, in other species (Kainulainen et al., 2012;



**FIGURE 7** | SlpB is required to achieve the effective mitigation of NF-κB activation in human intestinal epithelial cells. Percentage of NF-κB activation in HT-29 intestinal epithelial cells after stimulation by LPS ( $1 \text{ ng } \mu\text{L}^{-1}$ ) in the presence or absence of UF-derived EVs ( $1.0 \times 10^9 \text{ EVs ml}^{-1}$ ). WT: wild type *P. freudenreichii* CIRM-BIA 129-derived EVs,  $\Delta\text{SlpB}$ : isogenic mutant *P. freudenreichii* CIRM-BIA 129  $\Delta\text{SlpB}$ -derived EVs, 37°C: wild type *P. freudenreichii* CIRM-BIA 129-derived EVs incubated at 37°C for 1 h, 37°C + PK: wild type *P. freudenreichii* CIRM-BIA 129-derived EVs incubated at 37°C for 1 h in the presence of proteinase K. The values are normalized by the control conditions (stimulation by an inducer in the absence of EVs). One-way ANOVA followed by Tukey's multiple comparisons test: \* $P < 0.05$ ; \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ .

interesting to note that SlpB, Eno1 and GroL2 were found to be some of the most abundant EV proteins, which may be a further indication of the potentially beneficial roles exerted by CIRM-BIA 129 EVs on host cells. This is in accordance with the potential immunomodulatory role suggested for these proteins in a multi-strain and multi-omics study (Deutsch et al., 2017).

In order to investigate potential roles for EVs in the context of host-microorganism interactions, we conducted *in silico* predictions of interactions between the bacterial proteins identified in EVs and human proteins. We employed a machine learning-based method (intersppi), which relies on protein sequences and network properties, to identify patterns of classification into groups of interacting or non-interacting protein pairs (Lian et al., 2019). We also used a homology-based prediction of interacting pairs (interolog) that relies on the mapping of similarities to interaction databases and interaction transfers among homologs (Folador et al., 2014). Our results revealed a considerable difference between the methods in the number and nature of the interactions predicted. This difference was mainly due to the fact that the interolog methodology depends on data availability in interaction databases, such as STRING and INTACT, from which homology mapping is performed (Wang et al., 2012). The data may therefore have been biased by experimental work focused on specific aspects and organisms, as well as the conservation of proteins, which may affect homology identification. For example, metabolism-related proteins tend to be more conserved, so they are therefore overrepresented in interactions predicted using the interolog methodology. On the other hand, intersppi aims to capture more general patterns of protein binding, enabling *ab initio* predictions that are not reliant on the availability of prior data. However, it is still susceptible to training data bias and a certain probability of false positives (Keskin et al., 2016).

The predicted interactions mapped to several immunology-related KEGG terms, such as signal transduction, infectious diseases and the immune system, thus shedding light on a possible immunomodulatory role for *P. freudenreichii* EVs. These predictions corroborate some previous findings which associated the *P. freudenreichii* bacterium with immunomodulatory roles (Foligne et al., 2010; Deutsch et al., 2017; Do Carmo et al., 2017; Frohnmeyer et al., 2018; Rabah et al., 2018a). Interestingly, the predicted data also suggested that this immunomodulation could involve the NF-κB pathway, since the nuclear factor NF-κB p105 subunit (NFKB1, P19838) was the most frequent interacting human protein according to the intersppi predictions and also the interactions shared between the two methods. Regarding bacterial proteins previously reported as being immunomodulatory, Acn, Eno1, GroL2, HtrA1, SlpA, SlpB, and SlpE were predicted to interact directly with NFKB1 using the intersppi method. In addition, the interaction between Eno1 and NFKB1 was also predicted by interolog. Other proteins in the NF-κB pathway were also predicted to interact with Acn: the inhibitor of nuclear factor kappa-B kinase subunits alpha (IKKA) and beta (IKKB), as well as TIR domain-containing adapter molecule 1 (TICAM1). Moreover, interactions with toll-like receptors (e.g., TLR1, TLR4, TLR5, TL6) suggested that the immunomodulatory role of EVs might also occur at the receptor

Rodríguez-Bolaños and Perez-Montfort, 2019). As well as metabolism-related proteins, other proteins packed into EVs are also related to interactions between *P. freudenreichii* and the host: SlpB (PFCIRM129\_00700) and SlpE (PFCIRM129\_05460) surface-layer proteins, the BopA solute binding protein (PFCIRM129\_08120), internaline A (InIA, PFCIRM129\_12235), the hypothetical protein PFCIRM129\_10785 and the GroL2 chaperonin (PFCIRM129\_10100) (Le Maréchal et al., 2015; Deutsch et al., 2017; Do Carmo et al., 2017). It has been shown that SlpB mediates the adhesion of *P. freudenreichii* CIRM-BIA 129 to intestinal epithelial HT29 cells (Do Carmo et al., 2017), reduces LPS-induced IL-8 expression in HT-29 cells (Do Carmo et al., 2019) and participates in the induction of anti-inflammatory cytokines such as IL-10 in human peripheral blood mononuclear cells, mesenteric lymph nodes cells and epithelial HT29 cells (Foligne et al., 2010; Le Maréchal et al., 2015; Deutsch et al., 2017; Rabah et al., 2018a). Also, inactivation of the gene encoding SlpE suppresses IL-10 induction by *P. freudenreichii* CIRM-BIA 129 (Deutsch et al., 2017). It is

level. Briefly, PPI data (i.e., highly interacting NFKB1 protein, interactions involving bacterial proteins previously demonstrated to be immunomodulatory and interactions mapping to KEGG terms related to the immune response) suggested an ability of EVs produced by *P. freudenreichii* CIRM-BIA 129 to exert an immunomodulatory effect via the NF- $\kappa$ B pathway, which then needed to be confirmed *in vitro*.

When tested on HT-29 intestinal epithelial cells, we found that EVs exert an inhibitory effect on LPS-induced IL-8 secretion, as was previously observed with intact *P. freudenreichii* CIRM-BIA 129 cells (Do Carmo et al., 2019). Their effect was dose-dependent and unrelated to side effects of EVs on cell viability. This immunomodulatory response was mediated through modulation of the regulatory activity of the NF- $\kappa$ B transcription factor. The NF- $\kappa$ B pathway leads to the upregulation of proinflammatory genes, being targeted by diverse pathogens and probiotic bacteria (Hayden and Ghosh, 2012; Mitchell et al., 2016). Therefore, some probiotics can downregulate the production of these proinflammatory cytokines, acting at different steps along the NF- $\kappa$ B pathway: *L. rhamnosus* GG and *Lactobacillus delbrueckii* subsp. *bulgaricus* downregulated p38 and I $\kappa$ B expression, respectively (Giahi et al., 2012), *L. plantarum* LM1004 and *Lactobacillus casei* DN-114 001 modulated the nuclear translocation of NF- $\kappa$ B (Tien et al., 2006; Lee et al., 2019), *Bacteroides thetaiotaomicron* promoted the nuclear export of RelA (Kelly et al., 2004), VSL#3 inhibited proteasome degrading activity (Petrof et al., 2004), and *Bifidobacterium breve* C50 decreased the phosphorylation of p38-MAPK and I $\kappa$ B- $\alpha$  (Heuvelin et al., 2009). Probiotic strains were also shown to exhibit immunoregulatory effects via the modulation of TLR negative regulators of the NF- $\kappa$ B pathway (Lakhdari et al., 2011; Kanmani and Kim, 2019). Specifically, *Lactobacillus helveticus* SBT2171 was reported to inhibit NF- $\kappa$ B activation by inducing A20 expression via TLR2 signal in LPS-stimulated peritoneal macrophages (Kawano et al., 2019). *Lactobacillus acidophilus* was shown to regulate the inflammatory response induced by enterotoxigenic *E. coli* K88 in piglets, notably through the increased expression of Tollip, IRAK-M, A20, and Bcl-3 (Li et al., 2016). *Lactobacillus paracasei* was associated to the inhibition of pro-inflammatory cytokines production by monocyte-macrophages, via the induction of A20, SOCS1, SOCS3, and IRAK3 (Sun et al., 2017).

The precise mechanism by which EVs produced by *P. freudenreichii* CIRM-BIA 129 modulate NF- $\kappa$ B activity still needs to be elucidated, but our work has provided some clues. EVs do not exert an immunomodulatory effect when the NF- $\kappa$ B pathway is stimulated by other inducers (such as TNF- $\alpha$  and IL-1 $\beta$ ), indicating that EVs mitigate the activation of NF- $\kappa$ B via the LPS signaling pathway. These different ligands bind to specific receptors at the cell surface in order to activate the NF- $\kappa$ B pathway. Once bound, they use the same signal transduction mechanisms to activate the pathway. Therefore, EVs probably act at a level of the NF- $\kappa$ B pathway that is not common to the three inducers: TLR4, CD14, LBP, MD-2 and the TICAM1 and TICAM2 TIR domain-containing adaptor proteins. It is interesting to note that *in silico* prediction of protein-protein interactions predicted interactions with TLR4,

the cell-surface receptor for LPS, but not with the TNF- $\alpha$  and IL-1 $\beta$  receptors. Furthermore, proteinase-treated EVs conserved their immunomodulatory properties. Therefore, the EV-triggered inhibition of NF- $\kappa$ B does not signal through binding between EV surface exposed proteins and the LPS receptor (i.e., LBP, TLR-4, CD14, MD-2). One can suppose that non-proteinaceous inhibitors may also be involved. However, to date, the immunomodulatory properties of *P. freudenreichii* have been associated with proteins. Moreover, EVs produced by a  $\Delta$ slpB *P. freudenreichii* mutant partly lost their immunomodulation effects, indicating that several proteins, including SlpB, play a direct or indirect role in the anti-inflammatory response mediated by EVs. These results also suggest that these immunomodulatory proteins are packed into EVs and are not surface exposed. It cannot be excluded that immunomodulatory proteins interact directly with LPS receptors after their release from the lysis of EVs in the vicinity of cells, but it does seem more likely that they target specific intercellular components of the LPS-induced NF- $\kappa$ B pathway after EV uptake by membrane fusion or endocytosis (Mulcahy et al., 2014; Jefferies and Khalid, 2020).

It is now well recognized that EVs act as proxies of their parental cells. Accordingly, *P. freudenreichii* and its EVs share common features, notably their immunomodulatory effects mediated by SlpB. Whether *P. freudenreichii* also signals through the same pathway as its EVs constitutes a basis for further studies. Likewise, whether *P. freudenreichii* EVs exert immunomodulatory effects *in vivo*, as has been shown for the bacterium (Foligne et al., 2010; Rabah et al., 2018a; Do Carmo et al., 2019) is a challenging question that should be addressed in future research and with respect to potential EV-based probiotic applications. In sum, this study reflects efforts to demonstrate the widespread occurrence and functional diversity of EVs, particularly in a group of emerging EVs research, such as Gram-positive probiotic bacteria. It also contributes to a clearer understanding of the mechanisms associated with the probiotic traits of *P. freudenreichii* while opening up possibilities of employing bacterial-derived EVs for functional cargo delivery and for the development of novel probiotic products.

## DATA AVAILABILITY STATEMENT

Data can be found here: <https://data.inra.fr/privateurl.xhtml?token=98c864ee-5c59-4bb9-b57d-c09447187d38>.

## AUTHOR CONTRIBUTIONS

VR, GJ, YL, VC, and EG conceived and designed the experiments. VR, VB-B, JJ, BL, and HR performed the experiments. VR, EF, AN, JJ, and EG analyzed the data. FC, AN, JJ, VB-B, HB, NL, GJ, and EG gave practical suggestions to perform experiments. VC, YL, and EG contributed to funding acquisition. VR and EG wrote the original draft. All authors contributed to data interpretation, drafting the manuscript, critically revising the manuscript and approving its final version.

## FUNDING

This work has received a financial support from the INRAE (Rennes, France) and Institut Agro (Rennes, France). VR and BL were supported by the International Cooperation Program CAPES/COFECUB at the Federal University of Minas Gerais funded by CAPES – the Brazilian Federal Agency for the Support and Evaluation of Graduate Education of the Brazilian Ministry of Education (number 99999.000058/2017-03 and 88887.179897/2018-03, respectively).

## ACKNOWLEDGMENTS

This work benefited from the facilities and expertise of the MRic-TEM platform (<https://microscopie.univ-rennes1.fr>). The authors are grateful to Agnes Burel (University of

Rennes, BIOSIT – UMS 3480, US\_S 018, Rennes, France) and Chantal Cauty for sessions with the microscope. The authors would like to thank Ludovica Marinelli (INRAE, AgroParisTech, Paris-Saclay University, Micalis Institute, Jouy-en-Josas, France) for her technical advice on the NF- $\kappa$ B reporter cell line. The authors would also like to thank Victoria Hawken for English-language editing of the manuscript. The authors thank CNIEL (Centre National Interprofessionnel de l'Economie Laitière) for providing the ITG P20 strain.

## SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fmicb.2020.01544/full#supplementary-material>

## REFERENCES

Alvarez, C.-S., Badia, J., Bosch, M., Giménez, R., and Baldomà, L. (2016). Outer membrane vesicles and soluble factors released by probiotic *Escherichia coli* Nissle 1917 and commensal ECOR63 enhance barrier function by regulating expression of tight junction proteins in intestinal epithelial cells. *Front. Microbiol.* 7:1981. doi: 10.3389/fmicb.2016.01981

Bagos, P. G., Tsigros, K. D., Liakopoulos, T. D., and Hamodrakas, S. J. (2008). Prediction of lipoprotein signal peptides in gram-positive bacteria with a hidden markov model. *J. Proteome Res.* 7, 5082–5093. doi: 10.1021/pr800162c

Bateman, A. (2019). UniProt: a worldwide hub of protein knowledge. *Nucleic Acids Res.* 47, D506–D515. doi: 10.1093/nar/gky1049

Behzadi, E., Mahmoodzadeh Hosseini, H., and Imani Fooladi, A. A. (2017). The inhibitory impacts of *Lactobacillus rhamnosus* GG-derived extracellular vesicles on the growth of hepatic cancer cells. *Microb. Pathog.* 110, 1–6. doi: 10.1016/j.micpath.2017.06.016

Böing, A. N., van der Pol, E., Grootemaat, A. E., Coumans, F. A. W. W., Sturk, A., and Nieuwland, R. (2014). Single-step isolation of extracellular vesicles by size-exclusion chromatography. *J. Extracell. Vesicles* 3:23430. doi: 10.3402/jev.v3.23430

Brown, L., Wolf, J. M., Prados-Rosales, R., and Casadevall, A. (2015). Through the wall: extracellular vesicles in gram-positive bacteria, mycobacteria and fungi. *Nat. Rev. Microbiol.* 13, 620–630. doi: 10.1038/nrmicro3480

Cañas, M.-A., Fábrega, M.-J., Giménez, R., Badia, J., and Baldomà, L. (2018). Outer membrane vesicles from probiotic and commensal *Escherichia coli* activate NOD1-mediated immune responses in intestinal epithelial cells. *Front. Microbiol.* 9:498. doi: 10.3389/fmicb.2018.00498

Colliou, N., Ge, Y., Sahay, B., Gong, M., Zadeh, M., Owen, J. L., et al. (2017). Commensal *Propionibacterium* strain UF1 mitigates intestinal inflammation via Th17 cell regulation. *J. Clin. Invest.* 127, 3970–3986. doi: 10.1172/JCI95376

Cousin, F. J., Juan-Lanhouet, S., Thérêt, N., Brenner, C., Jouan, E., Le, M.-M. G., et al. (2016). The probiotic *Propionibacterium freudenreichii* as a new adjuvant for TRAIL-based therapy in colorectal cancer. *Oncotarget* 7, 7161–7178. doi: 10.18632/oncotarget.6881

Cousin, F. J., Louesdon, S., Maillard, M.-B., Parayre, S., Falentin, H., Deutsch, S.-M., et al. (2012). The first dairy product exclusively fermented by *Propionibacterium freudenreichii*: a new vector to study probiotic potentialities in vivo. *Food Microbiol.* 32, 135–146. doi: 10.1016/j.fm.2012.05.003

Deptula, P., Chamlagain, B., Edelmann, M., Sangsuwan, P., Nyman, T. A., Savijoki, K., et al. (2017). Food-like growth conditions support production of active vitamin B12 by *Propionibacterium freudenreichii* 2067 without DMBI, the lower ligand base, or cobalt supplementation. *Front. Microbiol.* 8:368. doi: 10.3389/fmicb.2017.00368

Deutsch, S. M., Mariadassou, M., Nicolas, P., Parayre, S., Le, G. R., Chuat, V., et al. (2017). Identification of proteins involved in the anti-inflammatory properties

of *Propionibacterium freudenreichii* by means of a multi-strain study. *Sci. Rep.* 7:46409. doi: 10.1038/srep46409

Do Carmo, F. L. R., Rabah, H., Cordeiro, B. F., Silva, S. H., da, Pessoa, R. M., et al. (2019). Probiotic *Propionibacterium freudenreichii* requires SlpB protein to mitigate mucositis induced by chemotherapy. *Oncotarget* 10, 7198–7219. doi: 10.18632/oncotarget.27319

Do Carmo, F. L. R., Rabah, H., Huang, S., Gaucher, F., Deplanche, M., Dutertre, S., et al. (2017). *Propionibacterium freudenreichii* surface protein SlpB is involved in adhesion to intestinal HT-29 cells. *Front. Microbiol.* 8:1033. doi: 10.3389/fmicb.2017.01033

Elhenawy, W., Debelyy, M. O., and Feldman, M. F. (2014). Preferential packing of acidic glycosidases and proteases into *Bacteroides* outer membrane vesicles. *MBio* 5, e00909-14. doi: 10.1128/mBio.00909-14

Folador, E. L., Hassan, S. S., Lemke, N., Barh, D., Silva, A., Ferreira, R. S., et al. (2014). An improved interolog mapping-based computational prediction of protein-protein interactions with increased network coverage. *Integr. Biol. (United Kingdom)* 6, 1080–1087. doi: 10.1039/c4ib00136b

Foligne, B., Deutsch, S.-M., Breton, J., Cousin, F. J., Dewulf, J., Samson, M., et al. (2010). Promising immunomodulatory effects of selected strains of dairy propionibacteria as evidenced in vitro and in vivo. *Appl. Environ. Microbiol.* 76, 8259–8264. doi: 10.1128/AEM.01976-10

Frohnmeier, E., Deptula, P., Nyman, T. A., Laine, P. K. S. S., Vihinen, H., Paulin, L., et al. (2018). Secretome profiling of *Propionibacterium freudenreichii* reveals highly variable responses even among the closely related strains. *Microb. Biotechnol.* 11, 510–526. doi: 10.1111/1751-7915.13254

Fukumoto, S., Toshimitsu, T., Matsuoka, S., Maruyama, A., Oh-Oka, K., Takamura, T., et al. (2014). Identification of a probiotic bacteria-derived activator of the aryl hydrocarbon receptor that inhibits colitis. *Immunol. Cell Biol.* 92, 460–465. doi: 10.1038/icb.2014.2

Gagnaire, V., Jardin, J., Rabah, H., Briard-Bion, V., and Jan, G. (2015). Emmental cheese environment enhances *propionibacterium freudenreichii* stress tolerance. *PLoS One* 10:e0135780. doi: 10.1371/journal.pone.0135780

Ge, Y., Gong, M., Zadeh, M., Li, J., Abbott, J. R., Li, W., et al. (2020). Regulating colonic dendritic cells by commensal glycosylated large surface layer protein A to sustain gut homeostasis against pathogenic inflammation. *Mucosal Immunol.* 13, 34–46. doi: 10.1038/s41385-019-0210-0

Gho, Y. S., and Lee, C. (2017). Emergent properties of extracellular vesicles: a holistic approach to decode the complexity of intercellular communication networks. *Mol. BioSyst.* 13:1291. doi: 10.1039/c7mb00146k

Giahi, L., Aumüller, E., Elmadafa, I., and Haslberger, A. G. (2012). Regulation of TLR4, p38 MAPkinase, I $\kappa$ B and miRNAs by inactivated strains of lactobacilli in human dendritic cells. *Benef. Microbes* 3, 91–98. doi: 10.3920/BM2011.0052

Grande, R., Celia, C., Mincione, G., Stringaro, A., Di Marzio, L., Colone, M., et al. (2017). Detection and physicochemical characterization of membrane vesicles (MVs) of *Lactobacillus reuteri* DSM 17938. *Front. Microbiol.* 8:1040. doi: 10.3389/fmicb.2017.01040

- 1369 Hayden, M. S., and Ghosh, S. (2012). NF- $\kappa$ B, the first quarter-century: remarkable  
1370 progress and outstanding questions. *Genes Dev.* 26, 203–234. doi: 10.1101/gad.  
1371 183434.111
- 1372 Heuvelin, E., Lebreton, C., Grangette, C., Pot, B., Cerf-Bensussan, N., and Heyman,  
1373 M. (2009). Mechanisms involved in alleviation of intestinal inflammation by  
1374 bifidobacterium breve soluble factors. *PLoS One* 4:e5184. doi: 10.1371/journal.  
1375 pone.0005184
- 1376 Huang, S., Rabah, H., Jardin, J., Briard-Bion, V., Parayre, S., Maillard, M.-B., et al.  
1377 (2016). Hyperconcentrated sweet whey, a new culture medium that enhances  
1378 *Propionibacterium freudenreichii* stress tolerance. *Appl. Environ. Microbiol.* 82,  
1379 4641–4651. doi: 10.1128/AEM.00748-16
- 1380 Huerta-Cepas, J., Forslund, K., Coelho, L. P., Szklarczyk, D., Jensen, L. J., Von  
1381 Mering, C., et al. (2017). Fast genome-wide functional annotation through  
1382 orthology assignment by eggNOG-mapper. *Mol. Biol. Evol.* 34, 2115–2122.  
1383 doi: 10.1093/molbev/msx148
- 1384 Huerta-Cepas, J., Szklarczyk, D., Heller, D., Hernández-Plaza, A., Forslund,  
1385 S. K., Cook, H., et al. (2019). EggNOG 5.0: A hierarchical, functionally and  
1386 phylogenetically annotated orthology resource based on 5090 organisms and  
1387 2502 viruses. *Nucleic Acids Res.* 47, D309–D314. doi: 10.1093/nar/gky1085
- 1388 Ishihama, Y., Oda, Y., Tabata, T., Sato, T., Nagasu, T., Rappsilber, J., et al. (2005).  
1389 Exponentially modified protein abundance index (emPAI) for estimation of  
1390 absolute protein amount in proteomics by the number of sequenced peptides  
1391 per protein. *Mol. Cell. Proteomics* 4, 1265–1272. doi: 10.1074/mcp.M500061-  
1392 MCP200
- 1393 Jefferies, D., and Khalid, S. (2020). To infect or not to infect: molecular  
1394 determinants of bacterial outer membrane vesicle internalization by host  
1395 membranes. *J. Mol. Biol.* 432, 1251–1264. doi: 10.1016/j.jmb.2020.01.008
- 1396 Kainulainen, V., Loimaranta, V., Pekkala, A., Edelman, S., Antikainen, J., Kylväjä,  
1397 R., et al. (2012). Glutamine synthetase and glucose-6-phosphate isomerase  
1398 are adhesive moonlighting proteins of *Lactobacillus crispatus* released by  
1399 epithelial cathelicidin LL-37. *J. Bacteriol.* 194, 2509–2519. doi: 10.1128/JB.  
1400 06704-11
- 1401 Kanmani, P., and Kim, H. (2019). Functional capabilities of probiotic strains on  
1402 attenuation of intestinal epithelial cell inflammatory response induced by TLR4  
1403 stimuli. *BioFactors* 45, 223–235. doi: 10.1002/biof.1475
- 1404 Kawano, M., Miyoshi, M., and Miyazaki, T. (2019). *Lactobacillus helveticus*  
1405 SBT2171 induces A20 expression via toll-like receptor 2 signaling and inhibits  
1406 the lipopolysaccharide-induced activation of nuclear factor- $\kappa$ B and  
1407 mitogen-activated protein kinases in peritoneal macrophages. *Front. Immunol.*  
1408 10:845. doi: 10.3389/fimmu.2019.00845
- 1409 Kelly, D., Campbell, J. I., King, T. P., Grant, G., Jansson, E. A., Coutts, A. G. P.,  
1410 et al. (2004). Commensal anaerobic gut bacteria attenuate inflammation by  
1411 regulating nuclear-cytoplasmic shuttling of PPAR- $\gamma$  and RelA. *Nat. Immunol.*  
1412 5, 104–112. doi: 10.1038/ni1018
- 1413 Kerrien, S., Aranda, B., Breuza, L., Bridge, A., Broackes-Carter, F., Chen, C., et al.  
1414 (2012). The IntAct molecular interaction database in 2012. *Nucleic Acids Res.*  
1415 40, D841–D846. doi: 10.1093/nar/gkr1088
- 1416 Keskin, O., Tuncbag, N., and Gursoy, A. (2016). Predicting protein-protein  
1417 interactions from the molecular to the proteome level. *Chem. Rev.* 116, 4884–  
1418 4909. doi: 10.1021/acs.chemrev.5b00683
- 1419 Kim, D. K., Lee, J., Simpson, R. J., Lötvall, J., and Ghos, Y. S. (2015a). EVpedia:  
1420 a community web resource for prokaryotic and eukaryotic extracellular vesicles  
1421 research. *Semin. Cell Dev. Biol.* 40, 4–7. doi: 10.1016/j.semcdb.2015.02.005
- 1422 Kim, J. H., Lee, J., Park, J., and Ghos, Y. S. (2015b). Gram-negative and Gram-  
1423 positive bacterial extracellular vesicles. *Semin. Cell Dev. Biol.* 40, 97–104. doi:  
1424 10.1016/j.semcdb.2015.02.006
- 1425 Kim, J.-H., Jeun, E.-J., Hong, C.-P., Kim, S.-H., Jang, M. S., Lee, E.-J., et al. (2016).  
1426 Extracellular vesicle-derived protein from *Bifidobacterium longum* alleviates  
1427 food allergy through mast cell suppression. *J. Allergy Clin. Immunol.* 137,  
1428 507–516.e8. doi: 10.1016/j.jaci.2015.08.016
- 1429 Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the  
1430 head of bacteriophage T4. *Nature* 227, 680–685. doi: 10.1038/227680a0
- 1431 Lakhdari, O., Cultrone, A., Tap, J., Gloux, K., Bernard, F., Dusko Ehrlich, S., et al.  
1432 (2010). Functional metagenomics: A high throughput screening method to  
1433 decipher microbiota-driven NF- $\kappa$ B modulation in the human gut. *PLoS One*  
1434 5:13092. doi: 10.1371/journal.pone.0013092
- 1435 Lakhdari, O., Tap, J., Béguet-Crespel, F., Le Roux, K., de Wouters, T., Cultrone,  
1436 A., et al. (2011). Identification of NF- $\kappa$ B modulation capabilities within human  
1437 intestinal commensal bacteria. *J. Biomed. Biotechnol.* 2011, 1–9. doi: 10.1155/  
1438 2011/282356
- 1439 Lan, A., Bruneau, A., Bensaada, M., Philippe, C., Bellaud, P., Rabot, S., et al.  
1440 (2008). Increased induction of apoptosis by *Propionibacterium freudenreichii*  
1441 TL133 in colonic mucosal crypts of human microbiota-associated rats treated  
1442 with 1,2-dimethylhydrazine. *Br. J. Nutr.* 100, 1251–1259. doi: 10.1017/  
1443 S0007114508978284
- 1444 Lan, A., Bruneau, A., Philippe, C., Rochet, V., Rouault, A., Hervé, C., et al.  
1445 (2007a). Survival and metabolic activity of selected strains of *Propionibacterium*  
1446 *freudenreichii* in the gastrointestinal tract of human microbiota-associated rats.  
1447 *Br. J. Nutr.* 97, 714–724. doi: 10.1017/S0007114507433001
- 1448 Lan, A., Lagadic-Gossmann, D., Lemaire, C., Brenner, C., and Jan, G. (2007b).  
1449 Acidic extracellular pH shifts colorectal cancer cell death from apoptosis to  
1450 necrosis upon exposure to propionate and acetate, major end-products of the  
1451 human probiotic propionibacteria. *Apoptosis* 12, 573–591. doi: 10.1007/s10495-  
1452 006-0010-3
- 1453 Langella, O., Valot, B., Balliau, T., Blein-Nicolas, M., Bonhomme, L., and Zivy, M.  
1454 (2017). X!TandemPipeline: a tool to manage sequence redundancy for protein  
1455 inference and phosphosite identification. *J. Proteome Res.* 16, 494–503. doi:  
1456 10.1021/acs.jproteome.6b00632
- 1457 Le Maréchal, C., Peton, V., Plé, C., Vroland, C., Jardin, J., Briard-Bion, V., et al.  
1458 (2015). Surface proteins of *Propionibacterium freudenreichii* are involved in its  
1459 anti-inflammatory properties. *J. Proteomics* 113, 447–461. doi: 10.1016/j.jprot.  
1460 2014.07.018
- 1461 Lee, J., Jung, I., Choi, J. W., Lee, C. W., Cho, S., Choi, T. G., et al. (2019). Micronized  
1462 and heat-treated *Lactobacillus plantarum* LM1004 stimulates host immune  
1463 responses via the TLR-2/MAPK/NF- $\kappa$ B signalling pathway in vitro and in vivo.  
1464 *J. Microbiol. Biotechnol.* 29, 704–712. doi: 10.4014/jmb.1812.12059
- 1465 Li, H., Zhang, L., Chen, L., Zhu, Q., Wang, W., and Qiao, J. (2016). *Lactobacillus*  
1466 *acidophilus* alleviates the inflammatory response to enterotoxigenic *Escherichia*  
1467 *coli* K88 via inhibition of the NF- $\kappa$ B and p38 mitogen-activated protein kinase  
1468 signaling pathways in piglets. *BMC Microbiol.* 16:273. doi: 10.1186/s12866-016-  
1469 0862-9
- 1470 Li, M., Lee, K., Hsu, M., Nau, G., Mylonakis, E., and Ramratnam, B. (2017).  
1471 *Lactobacillus*-derived extracellular vesicles enhance host immune responses  
1472 against vancomycin-resistant enterococci. *BMC Microbiol.* 17:66. doi: 10.1186/  
1473 s12866-017-0977-7
- 1474 Lian, X., Yang, S., Li, H., Fu, C., and Zhang, Z. (2019). Machine-Learning-based  
1475 predictor of human-bacteria protein-protein interactions by incorporating  
1476 comprehensive host-network properties. *J. Proteome Res.* 18, 2195–2205. doi:  
1477 10.1021/acs.jproteome.9b00074
- 1478 Liu, Y., Alexeeva, S., Defourny, K. A., Smid, E. J., and Abee, T. (2018a). Tiny  
1479 but mighty: bacterial membrane vesicles in food biotechnological applications.  
1480 *Curr. Opin. Biotechnol.* 49, 179–184. doi: 10.1016/j.copbio.2017.09.001
- 1481 Liu, Y., Defourny, K. A. Y., Smid, E. J., and Abee, T. (2018b). Gram-Positive  
1482 bacterial extracellular vesicles and their impact on health and disease. *Front.*  
1483 *Microbiol.* 9:1502. doi: 10.3389/fmicb.2018.01502
- 1484 Loux, V., Mariadassou, M., Almeida, S., Chiappello, H., Hammani, A., Buratti, J.,  
1485 et al. (2015). Mutations and genomic islands can explain the strain dependency  
1486 of sugar utilization in 21 strains of *Propionibacterium freudenreichii*. *BMC*  
1487 *Genomics* 16:296. doi: 10.1186/s12864-015-1467-7
- 1488 Lynch, J. B., and Alegado, R. A. (2017). Spheres of hope, packets of doom: the good  
1489 and bad of outer membrane vesicles in interspecies and ecological dynamics.  
1490 *J. Bacteriol.* 199:e00012-17. doi: 10.1128/JB.00012-17
- 1491 Mehdiani, A., Maier, A., Pinto, A., Barth, M., Akhyari, P., and Lichtenberg,  
1492 A. (2015). An innovative method for exosome quantification and size  
1493 measurement. *J. Vis. Exp.* 17:50974. doi: 10.3791/50974
- 1494 Mitchell, S., Vargas, J., and Hoffmann, A. (2016). Signaling via the NF $\kappa$ B system.  
1495 *Wiley Interdiscip. Rev. Syst. Biol. Med.* 8, 227–241. doi: 10.1002/wsbm.1331
- 1496 Molina-Tijeras, J. A., Gálvez, J., and Rodríguez-Cabezas, M. E. (2019). The  
1497 immunomodulatory properties of extracellular vesicles derived from probiotics:  
1498 a novel approach for the management of gastrointestinal diseases. *Nutrients*  
1499 11:1038. doi: 10.3390/nu11051038
- 1500 Mulcahy, L. A., Pink, R. C., and Carter, D. R. F. (2014). Routes and mechanisms  
1501 of extracellular vesicle uptake. *J. Extracell. Vesicles* 3:24641. doi: 10.3402/jev.v3.  
1502 24641
- 1503 Ojala, T., Laine, P. K. S., Ahlroos, T., Tanskanen, J., Pitkänen, S., Salusjärvi,  
1504 T., et al. (2017). Functional genomics provides insights into the role of  
1505

- 1483 *Propionibacterium freudenreichii* ssp. *shermanii* JS in cheese ripening. *Int. J.*  
1484 *Food Microbiol.* 241, 39–48. doi: 10.1016/j.ijfoodmicro.2016.09.022
- 1485 Okada, Y., Tsuzuki, Y., Narimatsu, K., Sato, H., Ueda, T., Hozumi, H., et al.  
1486 (2013). 1,4-Dihydroxy-2-naphthoic acid from *Propionibacterium freudenreichii*  
1487 suppressing macrophage-derived proinflammatory cytokines. *J. Leukoc. Biol.*  
1488 94, 473–480. doi: 10.1189/jlb.0212104
- 1489 Petrof, E. O., Kojima, K., Ropeleski, M. J., Musch, M. W., Tao, Y., De Simone, C.,  
1490 et al. (2004). Probiotics inhibit nuclear factor- $\kappa$ B and induce heat shock proteins  
1491 in colonic epithelial cells through proteasome inhibition. *Gastroenterology* 127,  
1492 1474–1487. doi: 10.1053/j.gastro.2004.09.001
- 1493 Rabah, H., Ferret-Bernard, S., Huang, S., Le Normand, L., Cousin, F. J., Gaucher, F.,  
1494 et al. (2018a). The cheese matrix modulates the immunomodulatory properties  
1495 of *Propionibacterium freudenreichii* CIRM-BIA 129 in healthy piglets. *Front.*  
1496 *Microbiol.* 9:2584. doi: 10.3389/fmicb.2018.02584
- 1497 Rabah, H., Ménard, O., Gaucher, F., do Carmo, F. L. R., Dupont, D., and Jan, G.  
1498 (2018b). Cheese matrix protects the immunomodulatory surface protein SlpB  
1499 of *Propionibacterium freudenreichii* during in vitro digestion. *Food Res. Int.* 106,  
1500 712–721. doi: 10.1016/j.foodres.2018.01.035
- 1501 Rabah, H., Rosa do Carmo, F., and Jan, G. (2017). Dairy propionibacteria: versatile  
1502 probiotics. *Microorganisms* 5:24. doi: 10.3390/microorganisms5020024
- 1503 Rakoff-Nahoum, S., Coyne, M. J., and Comstock, L. E. (2014). An ecological  
1504 network of polysaccharide utilization among human intestinal symbionts. *Curr.*  
1505 *Biol.* 24, 40–49. doi: 10.1016/j.cub.2013.10.077
- 1506 Raposo, G., and Stoorvogel, W. (2013). Extracellular vesicles: exosomes,  
1507 microvesicles, and friends. *J. Cell Biol.* 200, 373–383. doi: 10.1083/jcb.  
1508 201211138
- 1509 Rodríguez-Bolaños, M., and Perez-Montfort, R. (2019). Medical and veterinary  
1510 importance of the moonlighting functions of triosephosphate isomerase. *Curr.*  
1511 *Protein Pept. Sci.* 20, 304–315. doi: 10.2174/1389203719666181026170751
- 1512 Rubio, A. P. D., Martínez, J. H., Casillas, D. C. M., Leskow, F. C., Piuri, M., and  
1513 Pérez, O. E. (2017). *Lactobacillus casei* BL23 produces microvesicles carrying  
1514 proteins that have been associated with its probiotic effect. *Front. Microbiol.*  
1515 8:1783. doi: 10.3389/fmicb.2017.01783
- 1516 Shannon, P. (2003). Cytoscape: a software environment for integrated models of  
1517 biomolecular interaction networks. *Genome Res.* 13, 2498–2504. doi: 10.1101/  
1518 gr.1239303
- 1519 Sun, K.-Y., Xu, D.-H., Xie, C., Plummer, S., Tang, J., Yang, X. F., et al. (2017).  
1520 *Lactobacillus paracasei* modulates LPS-induced inflammatory cytokine release  
1521 by monocyte-macrophages via the up-regulation of negative regulators of NF-  
1522  $\kappa$ B signaling in a TLR2-dependent manner. *Cytokine* 92, 1–11. doi: 10.  
1523 1016/j.cyto.2017.01.003
- 1524 Switzer, R. C., Merrill, C. R., and Shifrin, S. (1979). A highly sensitive silver stain  
1525 for detecting proteins and peptides in polyacrylamide gels. *Anal. Biochem.* 98,  
1526 231–237. doi: 10.1016/0003-2697(79)90732-2
- 1527 Szklarczyk, D., Morris, J. H., Cook, H., Kuhn, M., Wyder, S., Simonovic, M.,  
1528 et al. (2017). The STRING database in 2017: Quality-controlled protein-protein  
1529 association networks, made broadly accessible. *Nucleic Acids Res.* 45, D362–  
1530 D368. doi: 10.1093/nar/gkw937
- 1531 Tartaglia, N. R., Breynne, K., Meyer, E., Cauty, C., Jardin, J., Chrétien,  
1532 D., et al. (2018). Staphylococcus aureus extracellular vesicles elicit  
1533 an immunostimulatory response in vivo on the murine mammary  
1534 gland. *Front. Cell. Infect. Microbiol.* 8:277. doi: 10.3389/fcimb.2018.  
1535 00277
- 1536 Tien, M.-T., Girardin, S. E., Regnault, B., Le Bourhis, L., Dillies, M.-A., Coppée,  
1537 J.-Y., et al. (2006). Anti-inflammatory effect of *Lactobacillus casei* on *Shigella*-  
1538 infected human intestinal epithelial cells. *J. Immunol.* 176, 3841.3–3841. doi:  
1539 10.4049/jimmunol.176.6.3841-b
- 1540 Toyofuku, M. (2019). Bacterial communication through membrane vesicles.  
1541 *Biosci. Biotechnol. Biochem.* 83, 1599–1605. doi: 10.1080/09168451.2019.16  
1542 08809
- 1543 Toyofuku, M., Nomura, N., and Eberl, L. (2019). Types and origins of bacterial  
1544 membrane vesicles. *Nat. Rev. Microbiol.* 17, 13–24. doi: 10.1038/s41579-018-  
1545 0112-2
- 1546 Wang, F., Liu, M., Song, B., Li, D., Pei, H., Guo, Y., et al. (2012). Prediction and  
1547 characterization of protein-protein interaction networks in swine. *Proteome Sci.*  
1548 10:2. doi: 10.1186/1477-5956-10-2
- 1549 Yu, C. S., Cheng, C. W., Su, W. C., Chang, K. C., Huang, S. W., Hwang, J. K.,  
1550 et al. (2014). CELLO2GO: a web server for protein subCELLular lOcalization  
1551 prediction with functional gene ontology annotation. *PLoS One* 9:e99368. doi:  
1552 10.1371/journal.pone.0099368
- 1553 **Conflict of Interest:** The authors declare that the research was conducted in the  
1554 absence of any commercial or financial relationships that could be construed as a  
1555 potential conflict of interest.
- 1556 *Copyright* © 2020 de Rezende Rodvalho, da Luz, Rabah, do Carmo, Folador,  
1557 Nicolas, Jardin, Briard-Bion, Blottière, Lapaque, Jan, Le Loir, de Carvalho Azevedo  
1558 and Guédon. This is an open-access article distributed under the terms of the Creative  
1559 Commons Attribution License (CC BY). The use, distribution or reproduction in  
1560 other forums is permitted, provided the original author(s) and the copyright owner(s)  
1561 are credited and that the original publication in this journal is cited, in accordance  
1562 with accepted academic practice. No use, distribution or reproduction is permitted  
1563 which does not comply with these terms.